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Abstract: Pancreatic enzyme supplements (PES) are used in chronic pancreatitis (CP) for 
correction of pancreatic exocrine insufficiency (PEI) as well as pain and malnutrition. The 
use of porcine pancreatic enzymes for the correction of exocrine insufficiency is governed by 
the pathophysiology of the disease as well as pharmacologic properties of PES. Variability in 
bioequivalence of PES has been noted on in vitro and in vivo testing and has been attributed 
to the differences in enteric coating and the degree of micro-encapsulation. As a step towards 
standardizing pancreatic enzyme preparations, the Food and Drug Administration now 
requires the manufacturers of PES to obtain approval of marketed formulations by April 
2010. In patients with treatment failure, apart from evaluating drug and dietary interactions 
and compliance, physicians should keep in mind that patients may benefit from switching to a 
different formulation. The choice of PES (enteric coated versus non-enteric coated) and the need 
for acid suppression should be individualized. There is no current standard test for evaluating 
adequacy of therapy in CP patients and studies have shown that optimization of therapy based 
on symptoms may be inadequate. Goals of therapy based on overall patient presentation and 
specific laboratory tests rather than mere correction of steatorrhea are needed.
Keywords: pancreatic exocrine insufficiency, chronic pancreatitis, pancreatic enzyme 
supplement
Chronic pancreatitis (CP) is a progressive inflammatory condition of the pancreas that 
is characterized by abdominal pain (usually) and is often associated with exocrine and 
endocrine insufficiency. The initiation of pancreatic enzyme supplements (PES) is 
common in the management of CP and other conditions associated with pancreatic enzyme 
insufficiency (PEI), such as cystic fibrosis (CF) or pancreatic surgery. Through this review 
we present the existing data and guidelines on the use of PES in CP. The initial portion 
of the article will address the physiologic effects of PES, followed by the physiochemical 
properties of these preparations and clinical recommendations regarding their use.
Physiologic effects of pancreatic exocrine 
insufficiency
Fat malabsorption
The progressive destruction of pancreatic acinar cells leads to PEI. The most common 
clinical manifestation of PEI is steatorrhea, defined as more than 7 grams of fecal fat per 
day while consuming a 100 g fat diet.1 Pancreatic fat malabsorption usually precedes 
malabsorption of other macronutrients in CP, and is related to various factors. There is Therapeutics and Clinical Risk Management 2009:5 508
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rapid degradation of pancreatic lipase due to the presence of 
pancreatic proteases and acid in the duodenum.2,3 In addition, 
in the acidic duodenal milieu, bile salt precipitation and 
subsequent adsorption to undigested food reduces the bile salt 
pool.4,5 And finally, CP patients are believed to have a defect in 
ileal mucosal absorption of bile salts, effectively reducing the 
availability of bile salts for enterohepatic circulation.6 A final 
factor contributing to pancreatic steatorrhea is the presence 
of neurohormonal disturbances resulting in gallbladder 
hypomotility and accelerated gastric and intestinal transit7–9 
(see section on Motility).
Steatorrhea occurs in CP only after the pancreatic enzyme 
output has diminished by 90% of the normal output.10,11 The 
large reserve capacity of the pancreas, noted in these earlier 
studies, may be due to the non-pancreatic gastric and lingual 
lipases.12 These enzymes, which play an insignificant role in 
fat digestion in healthy individuals, can contribute signifi-
cantly to the digestion of dietary triglycerides (up to 30%) 
in patients with PEI.
Approximately 50% of CP patients experience steatorrhea 
within a median of 10–12 years after the onset of CP, but this 
may vary based on the etiology of CP.13,14 Early studies classified 
CP into two broad types: alcoholic (ACP) or non-alcoholic 
(NACP) (which is further subdivided into early-onset and 
late-onset NACP) (see Figure 1). Early-onset NACP occurs in 
children and adolescents and is often characterized by pain, but 
with longer preservation of pancreatic function and later devel-
opment of calcifications as compared to alcoholic CP and late-
onset NACP. PEI is less common with NACP than ACP.14
Randomized placebo controlled trials have shown that 
treatment with PES improves steatorrhea, as measured 
by increased fat absorption, reduced fecal fat excretion, 
decreased stool weight and frequency, improved stool 
consistency and improved symptom scores.15–18 Other studies 
have demonstrated that patients receiving PES report weight 
gain and improved quality of life, and studies demonstrate 
decreased defecation rates,19 increased cholesterol absorption 
and improved enterohepatic cycling of bile salts.5,20
Pain
The pain in CP is the most debilitating symptom of the disease 
and often leads to malnutrition, especially if the pain is related 
to meals. ACP and early-onset NACP are more commonly 
associated with pain as compared to late-onset NACP.14 The 
pathogenesis of pain is multi-factorial and believed to be 
a result of perineural inflammation, visceral hyperalgesia, 
and increased pancreatic ductal and parenchymal pressure. 
Complications such as stones, strictures, and pseudocysts 
may also contribute to pain in CP.
Cholecystokinin (CCK) may play an important role in CP 
related pain. Normal physiology is such that CCK releasing 
peptide (CCKrp), which is produced in the duodenum, 
stimulates the release of CCK. In turn, CCKrp is degraded 
by pancreatic serine proteases. In CP patients with PEI, lack 
of serine proteases leads to uninhibited production of CCK, 
a potent stimulator of pancreatic enzymes. This is believed 
to result in increased pancreatic ductal and parenchymal 
pressure, and hence pain. Several animal21 and human22 
studies have supported the presence of this regulatory path-
way, while others have not.23,24 The potential pain benefit of 
PES in CP pain is based on restoring this negative feedback 
mechanism.
Randomized controlled trials have suggested that non-
enteric coated PES reduce pain in CP,25,26 whereas enteric 
coated forms are less beneficial.27–29 A meta-analysis did not 
support the use of PES for the relief of pain in all patients.30 
Late onset iCP
Early onset iCP
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p = 0.0008
p = 0.024
Years after onset
0 10 20 30
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Figure 1 Onset of pancreatic exocrine insufficiency in patients with alcoholic and nonalcoholic etiologies. Reproduced with permission from Layer P, Keller J. 2003. Lipase 
supplementation therapy: standards, alternatives, and perspectives. Pancreas, 26:1–7. Copyright © 2003 Lippincott Williams & Wilkins.
Abbreviations: CP, chronic pancreatitis; iCP, idiopathic chronic pancreatitis.Therapeutics and Clinical Risk Management 2009:5 509
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In the above studies, however, the patients with idiopathic 
CP and patients with less advanced disease (“small duct CP”) 
achieved the greatest pain relief with PES. Enzyme prepara-
tions with high protease content may be more effective in 
reducing pain, while enzyme preparations with high lipase 
content are more effective in patients with steatorrhea.31 It 
is recommended that even though PES are limited in their 
effectiveness in pain relief, the non enteric coated forms 
are worth a trial in patients with less advanced disease, and 
further studies are needed to define whether certain subsets 
of patients with painful CP are more likely to respond to 
enzyme therapy.
Motility disorders
Motility disorders are common in patients with CP, and 
are related to alterations in neurohormonal regulation. GI 
hormones such as CCK and pancreatic polypeptide (PP) are 
important in the regulation of GI motility.8,9 The endogenous 
release of these hormones is adversely affected by the pres-
ence of undigested food in the intestines. Abnormal CCK 
and PP levels have been observed in CP patients with PEI. 
In addition, the development of secondary (apancreatic) 
diabetes mellitus leading to autonomic neuropathy can further 
compromise GI motility.32
Abnormal motility patterns in CP patients include 
accelerated gastric emptying,7,33 altered post-prandial 
antroduodenal motility,9 and alterations in gallbladder 
motility (delayed gallbladder contraction and reduced 
gallbladder emptying).7,8 The severity of these abnormali-
ties is often related to the degree of PEI and their presence 
often compounds the maldigestion and abdominal discomfort 
associated with CP.
PES therapy is effective in normalizing the altered 
levels of GI hormones,7,34 and correcting accelerated gastric 
emptying7,33 and abnormal antroduodenal motility.8,35 The 
normalization of such motility disorders may be attributed 
to improved lipid digestion and ileal braking induced by 
breakdown products such as oleic acids, triglycerides and 
short chain fatty acids. Improvement in gallbladder contrac-
tion with PES has been demonstrated in some studies36,37 but 
not in others.7
Malnutrition
In CP patients with PEI, maldigestion of dietary macronutrients 
(fat, protein and carbohydrates) and poor oral intake lead to 
health problems associated with malnutrition. CP patients 
often suffer from malnutrition and have a low body mass 
index and asthenic body type.
Deficiencies in fat-soluble vitamins A, E and K may lead to 
symptoms such as impaired nighttime vision, cerebellar ataxia, 
and/or increased prothrombin time.38–40 When compared to 
healthy controls, CP patients have lower serum levels of 
vitamin D, decreased bone mineral density and an increased 
incidence of osteoporosis.41–43 In addition, they may suffer 
from vitamin B12 deficiency due to both impaired release of 
B12 from complexes and bacterial overgrowth (a frequent 
finding in CP patients).44
Atherogenic alteration in serum lipoproteins(low levels 
of HDL-C and Apo-A)45 along with lifestyle factors such as 
smoking and alcohol may account for the increased preva-
lence of life-threatening cardiovascular lesions seen in CP 
patients.46,47
Although elaborate trials are lacking, PES does help 
to ameliorate the malnutrition. A higher body weight and 
improved serum albumin levels have been demonstrated in 
CP patients who received PES.48 In malnourished CP patients 
with PEI, the optimization of PES therapy based on the results 
of C-13 Mixed Triglyceride breath test showed an improve-
ment in fat digestion, body weight, serum levels of retinol 
binding protein (RBP) and the normalization of prealbumin 
after one year of optimized therapy.49 In addition, serum HDL 
levels have been shown to rise significantly, whereas levels 
of cholesterol or triglycerides in other lipoproteins remained 
unchanged20 and this may have a cardioprotective effect. PES, 
however, is not sufficient for correcting fat soluble vitamin 
(A, D, E and K) deficiencies or B12 deficiency, without 
simultaneous vitamin supplementation.38,44
Endocrine insufficiency
Long-standing CP often culminates in brittle diabetes due 
to progressive destruction of the pancreas, and the clinical 
management of secondary (apancreatic) diabetes mellitus can 
be challenging.50 Carbohydrate malabsorption eases glucose 
intolerance, and the administration of PES may exacerbate 
diabetes. One randomized controlled trial with PES in 
patients with apancreatic diabetes revealed major difficul-
ties with controlling blood sugars on changing from active 
enzyme replacement to placebo and vice versa, suggesting 
that enzyme adjustment should be carefully supervised in 
a hospital.16 In another randomized controlled trial of insu-
lin-dependent diabetics with PEI, there were no significant 
differences in hemoglobin A1C, fasting glucose levels, or 
2-hour postprandial glucose levels in patients receiving PES 
as compared to those not receiving PES.51 A reduction in 
mild and moderate hypoglycemia was observed in patients 
receiving PES and the authors concluded that PES therapy Therapeutics and Clinical Risk Management 2009:5 510
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can be used safely in patients with diabetes mellitus and 
exocrine dysfunction.
effect on incretins
Incretins (mainly GLP-1 (glucagon like peptide-1) and 
GIP (glucose-dependent insulinotropic polypeptide)) are 
insulinotropic intestinal peptide hormones released in 
response to simple carbohydrates and lipids, that cause an 
increase in the amount of insulin released from the beta cells 
in the pancreas.52 PES has been shown to restore the GIP 
response in CP patients.53 An increase in GLP-1 has also been 
described following PES.54 The increase in incretin levels was 
accompanied by an increase in plasma insulin and c-peptide 
levels, but without a significant lowering of plasma glucose 
levels (Figure 2). Knop et al concluded that the postprandial 
response of incretins is preserved in CP patients, and may be 
enhanced by the increased absorption of nutrients facilitated 
by pancreatic enzyme replacement.
Pharmacology and clinical use 
of panceatic enzyme supplements
PeS preparations
Porcine pancreatic enzymes are the current standard of 
treatment for PEI, and when protected from exposure to 
gastric acid, porcine lipase will not be degraded in the 
stomach. Pancreatin and pancrelipase are the two primary 
forms of porcine PES available, and pancrelipase has higher 
enzyme content (see below). Bovine enzymes are a potential 
alternative for individuals who refuse to consume porcine 
products for religious or other cultural reasons.55 The bovine 
preparations, however, contain approximately 75% less 
lipase activity than the porcine and human preparations, and 
there is some concern about transmittable pathogens (Foot 
and mouth disease and Bovine spongiform encephalopathy) 
from bovine preparations.
Microbial preparations of pancreatic enzymes (lipase, 
protease, and amylase) also exist.56–59 Certain bacteria (eg, 
Burkholderia plantarii) and fungi (eg, Aspergillus niger, 
Rhizopus arrhizus) produce pancreatic enzymes with sub-
stantial lipolytic activity and greater resistance to gastric 
acid degradation. The microbial preparations do not require 
colipase for activation (see below for the importance of 
colipase).55 Of the microbial preparations fungal lipase is 
remarkably stable in the acidic gastric milieu, and is rapidly 
inactivated by bile acids and proteases whereas bacterial 
lipase has remarkable stability in both gastric and duodenal 
milieu, particularly in moderately acidic and neutral pH. 
In vitro studies have demonstrated bacterial lipase stability 
against proteases and bile salts and in vivo canine experiments 
show that bacterial lipase is more potent and efficacious than 
porcine PES.60–62 The efficacy of bacterial lipases is directly 
proportional to the fat content in the diet. The coefficient of 
fat absorption (explained below), which is about 70% with 
bacterial lipase and a low fat diet increases to about 90% 
with a high fat meal.58,59
A novel PES product, TheraCLEC-Total (TCT) contain-
ing a proprietary formulation of bacterial lipase and fungal 
protease and amylase, is being developed to aid the digestion 
of macronutrients.58,59 CF patients with PEI who were treated 
with TCT experienced improvements in fat and nitrogen 
absorption, with the greatest improvement in patients with 
baseline fat absorption of less than 40%. The most commonly 
reported adverse effects from TCT were mild gastrointestinal 
disorders and abnormal transaminases. Rarely, more seri-
ous pulmonary adverse effects and an episode of intestinal 
obstruction have also been reported. The mechanisms respon-
sible for these adverse effects are not known.
Human lipase genes have been transfected and expressed 
using recombinant adenovirus carrier in vitro, ex vivo as 
well as in vivo. These genes have produced large amounts 
of human lipase, and in the future, ectopic expression of 
human lipase in the pancreatobiliary system may become 
an available treatment modality.63
when to initiate PeS
PES should be initiated in patients suffering from CP and 
steatorrhea. In particular, the greatest benefit is seen in 
patients who experience weight loss and excrete greater 
than 15 g of fecal fat per day.64–66 A recent prospective trial 
was performed where the C-13 medium chain triglyceride 
breath test was used to optimize PES therapy in CP patients 
who excrete less than 15 g of fecal fat per day. The results 
showed a significant improvement in the nutritional status 
of patients at one year follow up.66 Other indications to con-
sider a trial of PES include patients with idiopathic or small 
duct CP who suffer from pain unresponsive to other simple 
treatment measures.
when to administer PeS
It is widely accepted that PES should be given at the time of 
meals. This was demonstrated in 1977, by DiMagno et al who 
compared two PES administration schedules (hourly admin-
istration versus prandial administration) in patients with CP. 
Prandial administration of PES was more convenient and was 
as effective as hourly administration in abolishing steatorrhea Therapeutics and Clinical Risk Management 2009:5 511
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Figure 2 Plasma glucose (A), plasma insulin (B), and plasma C-peptide (C) concentrations in patients with chronic pancreatitis (CP) and pancreatic exocrine insufficiency (PEI) 
following ingestion of a liquid meal over 15 min (0–15 min) with pancreatic enzyme substitution (PeS; day 1, ■) and without PeS (day 2, □). Punctuated curves (∆) represent 
healthy control subjects (Ctrl) given an equal liquid meal without PeS. Data are mean values ± SE. Insets:   AUC values. *Significant difference (p  0.05). Reproduced with 
permission from Knop FK, vilsboll T, Larsen S, et al 2007. increased postprandial responses of GLP-1 and GiP in patients with chronic pancreatitis and steatorrhea following 
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and perhaps more effective in abolishing azotorrhea.67 
A recent prospective crossover randomized controlled trial 
compared three different prandial administration schedules 
of enteric coated mini-microspheres (less than 2 mm in diam-
eter) in CP patients with PEI. The schedules were 4 capsules 
before meals, 4 capsules after meals and 4 capsules during 
meals (1 before–2 during–1 after meals).17 Fat digestion was 
optimal when the enzyme preparations were taken during or 
after meals and was better than the fat digestion observed 
when capsules were administered just before meals. Interest-
ingly, there was no difference in patient’s preference for the 
three dosing schedules in this study.
Role of colipase
Normal physiology mandates that colipase, a protein cofactor 
of lipase, is required in sufficient amounts in the small intes-
tine to digest fat.68 Although devoid of enzymatic activity, 
colipase promotes pancreatic lipase activity by anchoring the 
enzyme on the surface of lipid droplets. Isolated colipase defi-
ciency has been demonstrated as a sole cause of steatorrhea 
in patients with PEI69 and is a potential cause of treatment 
failure in patients receiving PES. All of the PES preparations 
commercially available in 1992 contained adequate quanti-
ties of colipase for effective lipid digestion.70
Role of simultaneous acid supression
The intraduodenal pH in untreated CP patients is acidic due to 
(1) increased production of gastric acid,71 (2) defective inhi-
bition of gastric acid secretion,72 and (3) impaired secretion 
of bicarbonate into the duodenum from diseased pancreatic 
ductal epithelial cells. The resulting acidic intraduodenal 
milieu is responsible for the irreversible inactivation of pan-
creatic lipase,73,74 and the decreased functioning of bile salts.64 
It has been demonstrated that patient response to conventional 
PES is enhanced if gastric acid secretion is suppressed.75
The need for additional therapy aimed at increasing 
intraduodenal pH to improve the response to PES is critical. 
This is most commonly accomplished using proton pump 
inhibitors (PPIs) and H2 receptor antagonists. When used 
concomitantly with ‘conventional’ PES preparations, acid 
suppression improves the concentration of lipase in the duo-
denum in patients with PEI.74 The use of acid suppression may 
appear unnecessary in patients receiving enteric coated forms 
of PES; however, some studies suggest that acid suppression 
is still required.76 It should be noted that the release of pan-
creatic enzymes from the enteric coating is dependent on the 
intraluminal pH (see section on enteric coated preparations). 
At the low intraduodenal pH levels seen in CP, dissolution 
of the coating of these enzymes in the duodenum is, at best, 
partial with a more complete dissolution occurring distally 
in the small bowel as the pH rises.15 Patients who receive 
concomitant acid suppression with enteric coated PES have 
improved duodenal delivery of PES and more efficient utiliza-
tion of the absorptive capacity of the intestines.77
Randomized controlled trials have demonstrated a sig-
nificant improvement in fecal fat excretion with both enteric 
coated and non enteric coated PES and with simultaneous 
acid suppression (cimetidine or omeprazole) as compared to 
PES monotherapy.6,73,77,78 DiMagno74 concluded that the addi-
tion of either H2 receptor antagonists or PPI to an adequate 
dose of PES will decrease fat malabsorption in most cases. 
One study suggested that if enteric coated mini-microsphere 
PES were administered with high dose PPI (omeprazole 
60 mg), lower doses (10,000 lipase U tid) of the PES could 
achieve equal reduction in fecal fat excretion, improvement 
in abdominal symptom score and general well being when 
compared to standard (20,000 U tid) doses.79
It should be noted that impaired protein assimilation has 
been described in patients treated with omeprazole.80 The 
improvement in fat digestion seen with PES may be at the 
cost of decreased efficiency of protein digestion with the use 
of acid suppression. This was demonstrated in a prospective 
crossover study where the use of acid suppression with PES 
was associated with a marked decrease in the fat-protein 
content ratio in stool,81 suggesting an increase in fat absorp-
tion with a decrease in protein absorption. This concern 
should be kept in mind when prescribing acid suppression 
to patients with PEI.
enteric coated and micro-encapsulated 
pancreatic enzyme products
The finding that acid degrades PES is well described.2 Along 
with the concomitant use of medication to suppress gastric 
acid, enteric coated PES preparations have been designed to 
resist degradation in the gastric lumen. The first generation 
of these preparations was the enteric coated tablet with a 
diameter of 11–20 mm, which did not show any additional 
benefit over conventional preparations.82,83 Scintigraphic and 
breath testing demonstrated poor gastric empyting of these 
preparations; a finding attributed to the large size of these 
early enteric coated preparations.84–86
The next generation of enteric coated preparations was 
coated microspheres. Each particle (over 2 mm in size) 
in the PES capsule was coated with its own acid resistant 
coating which was designed to stay intact at a pH of less 
than 4, and immediately released between a pH of 5.0–5.5, Therapeutics and Clinical Risk Management 2009:5 513
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thus theoretically improving duodenal delivery of the PES 
preparation.
No therapeutic benefit of these preparations was seen, 
due to failure of the larger microcapsules to exit the stom-
ach with the meal they were intended to accompany, and 
hence the mini-microsphere (particle size 1–3 mm) was 
designed.84 The small particle size ensured optimal mixing 
and synchronous delivery with food. Marked improvement 
in fat absorption was observed in a randomized controlled 
trial using mini-microsphere preparations;87 however, in a 
separate double blind multi-center cross-over study, there 
was no difference between the enteric coated microspheres 
and mini-microspheres in patients with PEI.88 Patients, 
though, preferred the mini-microsphere preparations over the 
microsphere preparations. Whether the use of these enteric 
coated mini-microsphere preparations adds any special 
advantage over the existing therapeutic modalities for the 
treatment of PEI with CP remains debatable.
The most recent innovation in the formulation of PES 
has been the development of enteric coated “buffered” 
microsphere preparations which have 1.5–2.5 mEq of bicar-
bonate per capsule. Two randomized clinical trials have been 
conducted comparing these preparations to standard enteric 
coated microsphere preparations in CF patients with PEI,89,90 
only one of which demonstrated reduction in steatorrhea 
with buffered PES.89
In vitro and in vivo studies have been performed on various 
commercially available PES preparations.91–93 Although most 
preparations had similar enzyme composition (ie, the quantity 
of amylase, lipase and protease), differences in dissolution 
properties have been observed. For example, even though 
each preparation tested contained the same amount of lipase, 
the amount of lipase released as a function of time and pH 
were found to be different, which was attributed to differences 
in the physiochemical properties of the enteric coating. The 
enteric coating may be detrimental to the release of pancreatic 
enzyme in vivo and may be associated with increased risk of 
complications (see below). Based on in vitro tests, Aloulou 
et al propose that the efficacy of enteric coated PES could be 
enhanced by adding unprotected enzymes. The efficacy of 
combining unprotected powder enzymes and enteric coated 
PES was not found to be superior to enteric coated micro-
spheres alone in patients with CF.94 This combination therapy, 
however, has not been investigated in patients with CP.
Dose and formulation
Since pancreatic steatorrhea does not occur until pancreatic 
lipase output is decreased by more than 90%,10 the initial 
dose recommendations for PES is based on achieving 10% of 
normal postprandial lipolytic activity in the duodenal lumen. 
Based on these recommendations, the PES preparation must 
be able to produce 60 IU/min of lipase activity in postprandial 
chyme throughout the digestive period. A dose of 25–40,000 
IU is thus recommended for the digestion of a regular meal55 
which may be increased up to 2–3 fold in cases where it 
appears to lack a therapeutic effect (Figure 3).
A recent study has suggested that even higher than 
recommended doses of PES may be needed to digest fats, 
as the specific activity of human pancreatic lipase on dietary 
triglycerides was found to be three times less potent in vivo 
than seen previously under experimental conditions.95 Based 
on these findings, the authors suggest that higher doses of 
lipase may be required to completely normalize fat digestion. 
PES preparations containing higher lipase levels have proven 
to be more useful than standard preparations in the correction 
of PEI.96–98 Enteric coated microspheres with increased lipase 
content are currently available; however, higher doses of PES 
may cause serious side effects. Fibrosing colonopathy has 
been described in CF children taking PES, and hence doses 
greater than 75,000 IU of lipase per meal are not currently 
recommended (see below).
Dietary interactions
The ingestion of dietary fiber is associated with a small but 
significant increase in fecal fat excretion in CP patients with 
PEI.99 Recommending a high fiber diet or fiber supplements 
in CP patients may be problematic, despite the CP patient’s 
tendency for constipation due to analgesic use. In addition, 
alcohol consumption has been noted to decrease lipase 
activity in CP patients by poorly characterized mechanisms. 
These levels recover in approximately 6 weeks in patients 
who abstain from alcohol.100 Therefore it is doubly important 
that all patients on PES abstain from alcohol.
Calcium and magnesium containing antacids are 
associated with the formation of calcium and magnesium 
soaps and the precipitation of glycine conjugated bile salts in 
the intestine.101 This leads to worsened steatorrhea in patients 
with PEI and thus such antacids are not recommended.
Treatment failures, patient compliance 
and alternatives
Lack of patient compliance may be a cause of treatment 
failure, and can be assessed clinically by measuring fecal 
chymotrypsin levels.55,102 In compliant patients not respond-
ing to PES, increasing the dose of PES by 2–3 fold along 
with distribution of calories across 5–6 smaller meals is Therapeutics and Clinical Risk Management 2009:5 514
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recommended. PES preparations containing higher lipase 
levels have proven to be more useful for steatorrhea and may 
be tried in patients who do not respond to standard prepara-
tions. Medium chain triglycerides are not recommended as 
they do not offer any additional improvement in lipid diges-
tion in patients receiving PES.103
Despite drug compliance and adequate dosing, treatment 
with PES alone in some patients with severe PEI will not lead 
to clinical improvement. Other factors may be responsible, 
either separately or in interplay with PEI. Such factors to 
consider include bacterial overgrowth of the small intestine, 
inadequate acid suppression, intestinal infections such as 
giardiasis, or other intestinal absorption disorders. Treat-
ment failures can also occur following the substitution of a 
preferred brand with the generic formulation of PES. The 
lack of bioequivalence among different PES preparations is 
attributed to differences in the physicochemical properties of 
the enteric coating104,105 and has been confirmed by in vitro 
and in vivo studies (see below).
There is no standardized technique to assess treatment 
adequacy in patients receiving PES. Despite an adequate 
clinical response of malabsorption and steatorrhea in patients 
receiving PES, malnutrition may persist. Fecal fat estimation 
is considered the most reliable measure of fat malabsorption 
and various techniques ranging from clinical observation106 
to the gold standard measures such as the van de Kramer 
method,107 the near infrared spectrometry108 and Nuclear mag-
netic Resonance (NMR) spectrometric fecal fat analysis109 
have been described. Indices such as the coefficient of fat 
absorption ((ingested fat – excreted fat)/ingested fat *100), 
and daily fat excretion (excreted fat/ingested fat * 100) can 
be derived from dietary and fecal fat estimation. Various 
other clinical (Body weight, nutritional status, frequency of 
bowel movements, stool character, abdominal pain, global 
disease symptom score, quality of life score) as well as 
laboratory indicators (fecal elastase, fecal chymotrypsin, etc) 
may be used to test adequacy of PES in various studies. Of 
the laboratory tests, fecal elastase is a useful non-invasive 
test for detection of PEI,110–112 but its usefulness in evaluating 
treatment compliance with PES has not been described.
Another test that has been used in various studies in 
patients with PEI is the C-13 mixed triglyceride (MTG) 
breath test.113 It is a highly sensitive, specific, accurate and 
simple non-invasive test of exocrine pancreatic function 
with excellent correlation between pancreatic lipase output 
in the duodenum and the 6-hour cumulative 13CO2 excretion 
in breath. The C-13 breath test has been used in trials as a 
measure of adequacy of PES therapy in asymptomatic CP 
Pancreatin microspheres
(Lipase: 25–40 kU/meal)
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unsuccessful
unsuccessful
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incompliant
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•giardiasis?
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Decrease fat intake to 50–75 g/d
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Figure 3 Current standard enzyme treatment of steatorrhea in chronic pancreatitis. Reproduced with permission from Layer P, Keller J. 2003. Lipase supplementation therapy: 
standards, alternatives, and perspectives. Pancreas, 26:1–7. Copyright © 2003 Lippincott Williams & Wilkins.Therapeutics and Clinical Risk Management 2009:5 515
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patients and adjustment of PES based on C-13 MTG breath 
test has been associated with improved nutritional status.77 
Thus, improvement in clinical symptoms alone may not 
accurately predict therapeutic adequacy of PES, and better 
indicators to insure therapeutic benefit with enzyme sup-
plementation are needed.
in vitro tests
The United States Pharmacopoeia114 has specific guidelines 
for in vitro assays for enzyme activity as well as dissolution 
characteristics for PES. The USP guidelines specify that each 
mg of Pancreatin contains no less than 2 USP units of lipase 
activity and 25 USP units of amylase and protease activity 
and each mg of pancrelipase contains no less than 24 USP 
units of lipase activity and 100 USP units of amylase and 
protease activity. Each capsule of these preparations should 
contain between 90% and 165% of the labeled lipase and not 
less than 90% of labeled activities of amylase and lipase92 
(Table 1). The enteric coating of these enzymes is designed 
such that it remains intact at a pH of less than 4.0 and 
should dissolve rapidly and completely once the threshold 
pH (between 5.0 and 5.5 as selected by the manufacturer) 
is reached.
In vitro and in vivo studies have been performed to 
evaluate the bioequivalence of PES using these recom-
mendations.91–93 All PES products evaluated in these tests 
were within the USP requirements for levels of amylase, 
lipase and protease and most preparations had far greater 
enzyme activity than the lower limit required by the USP. 
These studies raise the interesting concept of “overfill” seen 
with PES preparations to allow for enzyme deterioration 
during storage, so as to prolong “shelf life”. This difference 
in dissolution properties of the enteric coating (see below) 
influences the enzyme activity in vitro as observed in these 
studies, and may be responsible for the observed difference 
in in vivo potency of the PES preparations.
Food and Drug Administration (FDA) 
regulations
PES drug product marketing in the United States predates the 
1938 passage of the Federal Food, Drug, and Cosmetic Act. 
These drugs are required on a lifelong basis in patients with 
PEI to prevent malnutrition and associated complications, 
and it may be necessary to substitute a preferred product 
with a different or generic brand in patients with PEI for 
a variety of reasons. Unfortunately, therapeutic failures 
(gastrointestinal symptoms and fat malabsorption) have 
been noted in patients with CF after pharmacists substituted 
a preferred brand of PES with generic pancrelipase, which 
rapidly resolved after initial therapy was reinstituted.105
FDA’s review of data and information on pancreatic 
extract drug products115 found significant variations in bio-
availability among the various dosage forms and among 
products from different manufacturers of the same dosage 
form. In the last two decades, the FDA has been making 
efforts to regulate these inadequacies. On April 28, 2004, the 
FDA announced that all manufacturers of PES are required 
to submit a new drug application (NDA) and obtain approval 
by April 28, 2008, to be able to market these drug products. 
The approval deadline has recently been deferred until April 
28, 2010, if the manufacturers have investigational new 
drug (IND) applications on active status on or before April 
28, 2008, and have submitted an NDA on or before April 
28, 2009. With these new requirements, there was only one 
approved PES preparation. This product Cotazym® (Organon, 
NJ, USA) was given FDA approval in 1996 but was taken 
off the market in August 2001.
Adverse effects
Hyperuricemia and hyperuricosuria leading to dysuria and 
uric acid crystaluria have been described in CF patients 
receiving PES.116 Allergic reactions to the porcine proteins 
may also occur.117 A fibrosing colonopathy has been described 
in children with CF receiving doses of PES above 24,000 U 
of lipase/kg/day.118 Recent studies have demonstrated that 
intake of high doses of methacrylic copolymer used as acid 
resistant coating in PES rather than the lipase itself may 
be the cause of fibrosing colonopathy.119–121 This condition 
has also been reported in patients who have never received 
PES, but rather a different drug coated with methacrylic 
copolymer.122 Pancreatin extracts are also prone to form 
insoluble complexes with folic acid, with the result that folic 
acid deficiency can develop in patients receiving PES. More 
commonly seen adverse effects include nausea and diarrhea. 
PES are defined as pregnancy category B drugs, as there is 
inconclusive evidence for its use in lactation.123
Summary
Patients suffering from CP should be evaluated for the pres-
ence of PEI. PES is effective in the correction of steatorrhea 
and may have a role in reducing pain, improving motility, 
and correcting malnutrition in these patients. The choice 
of PES (enteric coated versus non-coated, tablets versus 
mini-microspheres, etc) and the need for acid suppression 
should be individualized. There is no current standard test 
for evaluating adequacy of therapy in CP patients and studies Therapeutics and Clinical Risk Management 2009:5 516
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Table 1 Commercially available pancreatic enzyme (pancrelipase) preparations (Reproduced with permission from Ferrone M, Raimondo M, 
Scolapio JS. 2007. Pancreatic enzyme pharmacotherapy. Pharmacotherapy, 27:910–20. Copyright © 2007 Pharmacotherapy Publications)
Produce (distributor) Enzyme Content/Unit Dose (USP units)
Lipase Amylase Protease
immediate-release formulations
  Pancrelipase tablets (various manufacturers) 8000 30,000 30,000
  Panokase tablets (various manufacturers) 8000 30,000 30,000
  Plaretase 8000 tablets (ethex, St. Louis, MO) 8000 30,000 30,000
  viokase 8 tablets (Paddock Labs, Minneapolis, MN) 8000 30,000 30,000
  viokase 16 tablets (Axcan Scandipharm, Birmingham, AL) 16,000 60,000 60,000
  viokase powdera (Axcan Scandipharm) 16,800 70,000 70,000
enteric-coated minimicrospheres
  Creon 5 SR capsules (Solvay Pharmceuticals, Marietta, GA) 5000 16,600 18,750
  Creon 10 SR capsules (Solvay Pharmceuticals) 10,000 33,220 37,500
  Creon 20 SR capsules (Solvay Pharmceuticals) 20,000 66,400 75,000
enteric-coated microspheres
  Lipram 4500 DR capsules (Global Pharmaceuticals,  
  Philadelphia, PA)
4500 20,000 25,000
  Pancrelipase capsules (various manufacturers) 4500 20,000 25,000
  Pangestyme eC capsules (ethex) 4500 20,000 25,000
  Ultrase capsules (Axcan Scandipharm) 4500 20,000 25,000
  Ku-Zyme HP capsules (Schwarz Pharma, Milwaukee, wi) 8000 30,000 30,000
  Lipram-PN10 DR capsules (Global Pharmaceuticals) 10,000 30,000 30,000
  Lipram-CR10 DR capsules (Global Pharmaceuticals) 10,000 33,200 37,500
  Palcaps 10 DR capsules (Carlsbad Technology, Carlsbad, CA) 10,000 33,200 37,500
  Pangestyme CN-10 DR capsules (ethex) 10,000 33,200 37,500
  Lipram-UL12 DR capsules (Global Pharmaceuticals) 12,000 39,000 39,000
  Pangestyme UL12 DR capsules (ethex) 12,000 39,000 39,000
  Pancrelipase capsules (various manufacturers) 16,000 48,000 48,000
  Pangestyme MT16 DR capsules (ethex) 16,000 48,000 48,000
  Panocaps MT 16 DR capsules (Carlsbad Technology) 16,000 48,000 48,000
  Lipram-PN16 DR capsules (Global Pharmaceuticals) 16,000 48,000 48,000
  Lipram-UL18 DR capsules (Global Pharmaceuticals) 18,000 58,500 58,500
  Pangestyme UL18 DR capsules (ethex) 18,000 58,500 58,500
  Lipram-PN20 DR capsules (Global Pharmaceuticals) 20,000 56,000 44,000
  Panocaps MT 20 DR capsules (Carlsbad Technology) 20,000 56,000 44,000
  Lipram-UL20 DR capsules (Global Pharmaceuticals) 20,000 65,000 65,000
  Pangestyme UL20 DR capsules (ethex) 20,000 65,000 65,000
  Lipram-CR20 DR capsules (Global Pharmaceuticals) 20,000 66,400 75,000
  Palcaps 20 DR capsules (Carlsbad Technology) 20,000 66,400 75,000
  Pangestyme CN-20 DR capsules (ethex) 20,000 66,400 75,000
enteric-coated microspheres with bicarbonate buffer
  Pancrecarb MS-4 DR capsules (Digestive Care, Bethlehem, PA) 4000 25,000 25,000
  Pancrecarb MS-8 DR capsules (Digestive Care) 8000 40,000 45,000
  Pancrecarb MS-16 DR capsules (Digestive Care) 16,000 52,000 52,000
enteric-coated microtablets
  Pancrease MT4 capsules (McNeil, Raritan, NJ) 4000 12,000 12,000
  Pancrease MT10 capsules (McNeil) 10,000 30,000 10,000
  Ultrase MT12 capsules (Axcan Scandipharm) 12,000 39,000 39,000
(Continued)Therapeutics and Clinical Risk Management 2009:5 517
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have shown that optimization of therapy based on symptoms 
alone may be inadequate. Goals of therapy based on overall 
patient presentation and specific laboratory tests rather than 
mere correction of steatorrhea are needed. Improved nutri-
tional status is seen in patients receiving pancreatic enzyme 
replacement therapy, and the use of PES along with other 
medical and surgical modalities of treatment will significantly 
improve quality of life of patients with PEI.
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